Protocol-driven multidetector SPECT/CT: integration of hybrid imaging into the routine workflow of whole-body bone scintigraphy in oncology patients

Clin Radiol. 2020 Jan;75(1):79.e1-79.e7. doi: 10.1016/j.crad.2019.09.128. Epub 2019 Oct 7.

Abstract

Aim: To analyse the additional clinical value of protocol-driven and selective use of multidetector single-photon-emission tomography/computed tomography (SPECT/CT) in oncology patients undergoing whole-body bone scintigraphy (BS) and to analyse reporter confidence in diagnosis with and without SPECT/CT.

Materials and methods: During a 2-year period, 2,954 whole-body BS examinations were performed in oncology patients, with 444 (15%) undergoing additional protocol-driven SPECT/CT. Retrospective evaluation of planar BS and SPECT/CT images was performed by two experienced dual-trained nuclear medicine radiologists. The BS and SPECT/CT images were graded blindly using a five-point scale designed to evaluate the likelihood of a lesion being benign or malignant. Interpretation was applied on a per-patient basis.

Results: There was a 74.5% increase in definitive diagnostic classification and a 26.6% reduction in equivocal findings with SPECT/CT when compared to BS alone (p<0001). Of cases initially classified as "probably benign" on BS, 5.1% (10/193) were reclassified to "probably malignant" (1%) or "malignant" (4.1%) using the SPECT/CT data. The highest impact in reporter confidence was seen with SPECT/CT in the interpretation of lesions within the pelvis (34%), ribs (23%), lumbar spine (22%), and thoracic spine (21%).

Conclusion: Protocol-driven, selective use of SPECT/CT imaging to augment planar BS reduces equivocal findings and improves reporter confidence whilst minimising the impact on patient and reporting workflows.

MeSH terms

  • Aged
  • Algorithms
  • Bone Neoplasms / diagnostic imaging*
  • Bone Neoplasms / secondary*
  • Clinical Protocols
  • Diagnosis, Differential
  • Female
  • Humans
  • Male
  • Positron Emission Tomography Computed Tomography / methods*
  • Radiopharmaceuticals
  • Technetium Tc 99m Medronate
  • Whole Body Imaging
  • Workflow

Substances

  • Radiopharmaceuticals
  • Technetium Tc 99m Medronate